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Abstract
Epithelial ovarian cancer (EOC) is the most lethal of all gynecological malignancies in the UK. Recent evidence has shown 
that there is potential for immunotherapies to be successful in treating this cancer. We have previously shown the effective 
application of combinations of traditional chemotherapy and CAR (chimeric antigen receptor) T cell immunotherapy in 
in vitro and in vivo models of EOC. Platinum-based chemotherapy synergizes with ErbB-targeted CAR T cells (named T4), 
significantly reducing tumor burden in mice. Here, we show that paclitaxel synergizes with T4 as well, and look into the 
mechanisms behind the effectiveness of chemo-immunotherapy in our system. Impairment of caspase activity using pan-
caspase inhibitor Z-VAD reveals this chemotherapy-induced apoptotic pathway as an essential factor in driving synergy. 
Mannose-6-phosphate receptor-mediated autophagy and the arrest of cell cycle in G2/M are also shown to be induced by 
chemotherapy and significantly contributing to the synergy. Increased expression of PD-1 on T4 CAR T cells occurred 
when these were in culture with ovarian tumor cells; on the other hand, EOC cell lines showed increased PD-L1 expression 
following chemotherapy treatment. These findings provided a rationale to look into testing PD-1 blockade in combination 
with paclitaxel and T4 immunotherapy. Combination of these three agents in mice resulted in significant reduction of tumor 
burden, compared to each treatment alone. In conclusion, the mechanism driving synergy in chemo-immunotherapy of EOC 
is multifactorial. A deeper understanding of such process is needed to better design combination therapies and carefully 
stratify patients.
Keywords CAR T cells · Ovarian cancer · Apoptosis · In vivo models · Combination chemo-immunotherapy · Anti-PD-1
Abbreviations
3-MA  3-Methyladenine
BLI  Bioluminescence imaging
EOC  Epithelial ovarian cancer
GTP  Guanosine triphosphate
Luc  Luciferase
M6PR  Mannose-6-phosphate receptor
Z-VAD  Carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]- 
fluoromethylketone
Introduction
Epithelial ovarian cancer (EOC) is the fifth commonest 
malignancy in women with up to a quarter of a million 
new diagnoses per year worldwide [1, 2]. It presents at 
a late stage in up 75% of the cases [3]. Overall, 5-year 
survival has improved over the past few years but it is still 
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low at around 40% and even less for advanced disease [4]. 
Current management of the disease is largely age- and 
stage-dependent and involves debulking surgery followed 
by (or sometimes preceded by) platinum-based chemother-
apy, with or without a taxane. Poor survival is thought to 
be attributed to various factors including the non-specific 
symptoms of the disease, the advanced disease stage at 
diagnosis and acquisition of chemo-resistance following 
treatment [5–8]. There is therefore a need for novel, more 
targeted and personalized therapies.
Immunotherapy is an exciting new avenue and its use 
is gaining huge momentum in oncology with adoptive T 
cell therapy showing great promise in some cancers such 
as metastatic melanoma [9].
We have previously shown the successful use of chi-
meric antigen receptor (CAR) T cells in EOC as well as 
in other tumor models, in vitro and in vivo [10, 11]. We 
developed a CAR (T4) targeting ErbB homo- and hetero-
dimers [12], which have been shown to be upregulated in 
EOC [13–16]. T4 cells were able to mediate effective anti-
tumor activity in EOC in vitro and in our ovarian cancer 
mouse model [10]. Combining T4 cells with carboplatin or 
cisplatin resulted in even better killing of tumor cells and 
this interaction is thought to be synergistic [10]; however, 
the mechanism for this interaction remains unclear.
There is growing evidence that chemotherapy may be 
immunomodulatory, depending on the dosage and sched-
ule administered [17–19]. It can alter the tumor microenvi-
ronment by modulating tumor antigen expression, antigen 
processing and T cell activation [20, 21].
Combination of different therapeutic strategies is 
becoming the way forward in the field of cancer immuno-
therapy. A relevant example is that of immune checkpoint 
inhibitors [22, 23].
A better understanding of the mechanisms that might 
drive synergy and determine clinical success is urgent 
and necessary to better carefully design such combination 
strategies and predict patient response.
Having previously shown a synergistic relationship 
between platinum-based agents ad T4 cells, we inves-
tigated if paclitaxel, the other main chemotherapeutic 
agent used in the treatment of EOC, would show a similar 
effect. We hypothesized that the effects of chemotherapy 
on processes such as apoptosis, autophagy and cell cycle 
are responsible for sensitization of EOC to immunothera-
pies such as T4 CAR T cells. We investigated the effect 
of impairing such processes in an effort to elucidate the 
mechanisms for the observed synergistic chemo-immuno-
therapy interactions. Additionally, our findings provided 
a rationale to look into augmenting this chemo-immuno-
therapy combination with PD-1 blockade and we tested 
this novel three-agent approach in our in vitro and in vivo 
EOC models.
Materials and methods
Cell culture
Human epithelial ovarian cancer cell lines were grown 
in RPMI-1640 media (Sigma-Aldrich, Poole, UK) with 
10% FBS (Sigma-Aldrich, Poole, UK) and l-glutamine 
200 mM, penicillin 10,000 units, streptomycin 10 mg/mL 
solution (Sigma-Aldrich, Poole, UK). The firefly luciferase 
(luc)-expressing SKOV-3 cell line (SKOV-3-luc) was pur-
chased for this work from Cell Biolabs Inc. (California, 
USA). OVCAR-4 cell line was available in the laboratory 
of Sadaf Ghaem-Maghami. The retroviral vector packag-
ing cell line, PG13, which either expressed the sequence 
for T4 or mock constructs, was maintained in DMEM sup-
plemented with 10% FBS, l-glutamine 200 mM, penicillin 
10,000 units, streptomycin 10 mg/mL solution and cipro-
floxacin 5 µg/mL (CIPRO; Bayer, New Jersey, USA). This 
packaging cell line was kindly supplied by the laboratory 
of John Maher (King’s College London, UK) [10]. The 
J591 scFv (used to generate the mock CAR) was supplied 
under MTA to John Maher by Neil Bander (Cornell Uni-
versity, New York). All cells were cultured in 37 °C with 
5%  CO2.
Retroviral transduction of human T cells
Transduction of human T cells, isolated from healthy vol-
unteers’ blood, was performed as previously described by 
Davies et al. [12].
Flow cytometry
Antibodies used for the analysis of cell surface markers 
were PE-conjugated mouse anti-human Mannose-6-phos-
phate receptor (M6PR) antibody (Abcam, Cambridge, UK) 
for tumor cells, PE-conjugated mouse anti-human CD279 
(PD-1, BD Biosciences Pharmingen, California, USA) and 
APC-conjugated mouse anti-human CD3 (BD Biosciences 
Pharmingen, California, USA) for T cells.
For detecting apoptosis, tumor cells were stained with 
FITC-Annexin V (BD Biosciences Pharmingen, Califor-
nia, USA) and 7-AAD (7-amino-actinomycin; BD Bio-
sciences Pharmingen, California, USA).
For cell cycle analysis, tumor cells, following the addi-
tion of the desired drug treatments, were collected by 
trypsinization and then centrifuged. The cell pellet was 
resuspended in 300 µL ice-cold 70% ethanol and incubated 
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in the dark at 4 °C for 24 h. The cell pellet was then resus-
pended in propidium iodide 1 mg/mL (Sigma-Aldrich, 
Poole, UK), RNase A 1 mg/mL (Invitrogen, Paisley, UK) 
and PBS, and incubated for 30 min.
10,000 events were acquired on a FACSCalibur flow 
cytometer (Becton Dickinson Immunocytometry Systems, 
California, USA) with CellQuest Pro Software version 
4.0.2 (Becton Dickinson, California, USA). FlowJo soft-
ware version 6.4.7 (Tree Star Inc, Oregon, USA) was used 
for analysis.
For cell cycle analysis, gating was performed using for-
ward and side scatter dot plots on the tumor cell popula-
tion. A second gate was setup to exclude doublets on a 
dot-plot of pulse width versus pulse area. PI fluorescence 
was plotted against cell count to distinguish between the 
various phases of the cell cycle.
For the analysis of tumor cell surface markers after 
tumor:T cell co-culture, gating was performed using for-
ward and side scatter dot plots on the tumor cell popu-
lation, avoiding the T cell population, and CD3-positive 
cells were excluded.
Cell viability assay
Cell viability was quantified using a MTT (Sigma-Aldrich, 
Poole, UK) assay. Tumor cells were seeded onto a 96-well 
plate at a density of 1 × 104 tumor cells per well and cul-
tured for 24 h. Paclitaxel (Teva, Castleford, UK) or car-
boplatin (Fresenius Kabi Oncology, Hampshire, UK) 
were added the following day, diluted in RPMI media 
at the required concentrations. Other drugs such as 25 
∝M Z-VAD (carbobenzoxy-valyl-alanyl-aspartyl-[O-
methyl]-fluoromethylketone: R&D), 5 mM 3-methylad-
enine (3-MA; Sigma-Aldrich, Poole, UK) or Thiostrepton 
(Sigma-Aldrich, Poole, UK) were added at this stage. Cells 
were incubated for a further 48 h, after which the super-
natant was removed and T cells were added to the wells. 
For experiments looking at the effect of PD-1 antibody, 
T cells were incubated with anti-PD-1 antibody 20 µg/µL 
(BMS-936558; Bristol-Myers-Squibb, New York, USA) 
for 1 h before being added to the tumor cells and being 
co-cultured for 24 h. The supernatant was removed and 
MTT 500 µg/mL (Sigma-Aldrich, Poole, UK) was added 
for 2–3 h. Formazan crystals were resuspended in 90 µL of 
dimethyl sulfoxide (DMSO; Sigma-Aldrich, Poole, UK). 
Absorbance was measured at a wavelength of 570 nm 
using an OPTImax tunable microplate reader programmed 
with Softmax Pro software version 4.2 (Molecular Devices 
Corporation, California, USA). Tumor cell viability was 
calculated as follows: (absorbance of monolayer cultured 
with T cells/absorbance of untreated monolayer alone) × 
100.
Caspase activity
Apo-Tox-Glo Triplex kit (Promega, California, USA) was 
used to measure tumor cell viability and caspase-3/7 activ-
ity following the manufacturer’s protocol. Both fluores-
cence (for cell viability) and luminescence (for caspase 
activation) were measured on a LUMIstar OPTIMA micro-
plate reader programmed with OPTIMA software version 
2.20R2 (BMG Labtech, Aylesbury, UK) and caspase activ-
ity was normalized to cell viability.
Quantitative polymerase chain reaction (q‑PCR)
RNA extraction and cDNA conversion were performed 
using RNeasy Micro Kit (Qiagen, California, USA) and 
High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Paisley, UK), respectively, as per the manu-
facturers’ instructions. Real-time PCR was performed 
using 7900HT Real-Time PCR System (Applied Biosys-
tems, Paisley, UK) and analyzed using the 2 (-delta delta 
C(T)) method. qPCR primers sequences were as follow: 
GAPDH sense 5′-AGC CAC ATC GCT CAG ACA C-3′, anti-
sense 5′-GCC CAA TAC GAC CAA ATC C-3′; M6PR sense 
5′-CCA CAC TTC CAC AGA TGT TGA-3′, antisense 5′-CCG 
AGC TGT GCA GTT ATA CAT-3′.
Enzyme‑linked immunosorbent assay (ELISA)
Conditioned cell culture medium was analyzed for human 
IFN-γ and Granzyme B using the Human IFN gamma 
ELISA Ready-SET-Go (eBiosciences, California, USA) 
and the Human Granzyme B Platinum ELISA (eBio-
sciences, California, USA) kits, respectively, according 
to manufacturer’s protocol.
Confocal imaging
SKOV-3-luc cells were seeded on 13 mm diameter glass 
cover slips at a seeding density of 3 × 104 cells per slide 
and were treated with paclitaxel or carboplatin with and 
without 3-MA for 48 h as described previously. The cells 
were fixed with 4% paraformaldehyde for 5 min, washed 
with PBS containing 1% FBS and stained with mouse anti-
human M6PR primary antibody (Abcam, Cambridge, UK) 
and Alexa Fluor 488 Goat anti-mouse secondary antibody 
(Life Technologies, Paisley, UK). The cells were mounted 
on a glass slide using ProLong Gold Antifade Mountant 
(Life Technologies, Paisley, UK) and imaged using a Leica 
TCS SP5 Confocal Laser Scanning Microscope.
 Cancer Immunology, Immunotherapy
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In vivo studies
SCID Beige mice were inoculated with 1 × 106 SKOV-3-
luc tumor cells intraperitoneally (i.p.) and tumor engraft-
ment was confirmed 4 days later using bioluminescence 
imaging (BLI; IVIS Lumina Series III, PerkinElmer, Mas-
sachusetts, USA). The tumors were allowed to graft for 21 
days before treatment was initiated. There were five mice 
in each group (except for the PBS group where there were 
only two mice). One group was treated with paclitaxel 
(10 mg/kg) on day 21, followed by 2.5 × 106 T4 cells on 
day 23 and anti-PD-1 antibody (10 mg/kg) every 48 h. The 
other groups received either PBS, paclitaxel alone on day 
21 followed by PBS, T4 cells alone on day 23, paclitaxel 
on day 21 followed by T4 cells on day 23, or T4 cells on 
day 23 followed by anti-PD-1 antibody every 48 h. BLI 
was performed weekly to assess tumor response to treat-
ment and Living Image software (PerkinElmer, Massachu-
setts, USA) was used for analysis. Mice were injected i.p. 
with 150 mg/kg d-Luciferin (Caliper life Sciences, Mas-
sachusetts, USA) and imaged whilst being anaesthetized 
with isoflurane (Isoflo; Abbott Laboratories Ltd, Kent, 
UK). Image acquisition was conducted on a 25-cm field 
of view with medium binning and auto-exposure. Animals 
were inspected daily for signs of ill health. Mice were 
culled when experimental endpoints had been achieved or 
if they became symptomatic as a result of tumor burden.
Statistical analysis
Statistical analysis was carried out using Graphpad Prism 
software version 6.00 (Prism, California, USA) using a two-
way ANOVA test to compare mean differences between two 
independent variables. Results are expressed as mean ± SEM 
based on three or more repeats. p < 0.05 was considered sta-
tistically significant.
Results
Paclitaxel, as well as carboplatin, enhances 
sensitivity to T4 immunotherapy
To determine the effect of combining chemotherapy, in the 
form of carboplatin or paclitaxel, with T4 immunotherapy, 
tumor cells were treated with either drug for a period of 48 h 
followed by the addition of T4 cells for a further 24 h. Cell 
viability was measured by MTT assay, as described above. 
Treatment of SKOV-3-luc cells with paclitaxel (Fig. 1a) or 
carboplatin (Fig. 1b) followed by the addition of T4 cells 
resulted in a significant reduction in tumor cell viability. At 
each dose tested, the results show a significant reduction 
in cell viability with combination treatment compared to 
individual therapies. This same effect was seen in OVCAR-4 
(Fig. 1c, d). The doses used for both drugs were on either 
side of the IC-50 for the cell lines. Interestingly, the signifi-
cant reduction in cell viability is even more prominent at the 
Fig. 1  In vitro assessment of 
anti-tumor activity of T4 cells 
against ovarian tumor cell lines 
in combination with paclitaxel 
or carboplatin. a, b SKOV-
3-luc cell viability following 
combination treatment of T4 
and paclitaxel (a) or carbopl-
atin (b). c, d OVCAR-4 cell 
viability following combination 
treatment of T4 and paclitaxel 
(c) or carboplatin (d). Data 
show mean ± SEM using T cells 
from separate donors (n = 6); 
**p < 0.01, ***p < 0.001, 
****p < 0.0001
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lower doses, compared to the higher doses. The effect was 
replicated in our in vivo tumor model where the combination 
of paclitaxel and T4 immunotherapy resulted in a significant 
reduction in tumor burden (Fig. 6b).
Impairment of apoptotic caspase pathways partially 
reverses synergistic killing of ovarian cancer cells
To investigate the mechanisms by which chemotherapy 
appears to sensitize ovarian cancer cell lines to T4 immu-
notherapy, we assessed tumor cell surface expression of 
annexin V and caspase 3/7 activity as markers of apop-
tosis. Figure 2a shows a significant increase in the tumor 
cell surface expression of annexin V after treatment with 
chemotherapy as measured by flow cytometry; furthermore, 
there was a significant increase in tumor cell caspase 3/7 
activity with increasing doses of chemotherapy (Fig. 2b, c). 
Such increase in cell surface annexin V and caspase activity 
was reversed by treatment with Z-VAD [24], a pan-caspase 
inhibitor which binds irreversibly to caspase proteases, 
inhibiting the induction of apoptosis (Fig. 2a–c).
To test our hypothesis that chemotherapy-induced apop-
tosis contributes to the synergistic effect of our combination 
therapy, SKOV-3-luc cells were treated with chemotherapy 
and Z-VAD for 48 h followed by treatment with T4 cells 
(Fig. 2d, e). Z-VAD caused a partial reversal in the reduc-
tion in tumor cell viability induced by combination treat-
ment with chemotherapy and T4 cells. The reversal was 
Fig. 2  Induction of apoptosis by chemotherapy as a possible mech-
anism for synergy between chemotherapy and T4 cells. a Flow 
cytometry analysis of Annexin V expression on SKOV-3-luc tumor 
cell surface following treatment with various doses of paclitaxel or 
carboplatin ± the pan-caspase inhibitor Z-VAD. b, c Caspase 3/7 
activity following treatment of SKOV-3-luc with various doses of 
paclitaxel (b) or carboplatin (c) ± Z-VAD. d, e SKOV-3-luc cell via-
bility following combination treatment of T4 and paclitaxel (d) or 
carboplatin (e) ± Z-VAD. Data show mean ± SEM (n = 3); *p < 0.05, 
***p < 0.001, ****p < 0.0001
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almost complete; however, the fact that tumor cell viabil-
ity did not entirely return to base levels might suggest that 
apoptosis is not the only mechanism of sensitization to T4 
immunotherapy.
Shuttling of M6PR (mannose‑6‑phosphate receptor) 
to the ovarian tumor cell surface is necessary 
for synergistic killing by chemo‑immunotherapy
It has been suggested in the literature that chemotherapy 
induces an upregulation in tumor cell surface M6PR, facili-
tating cytotoxic killing by T cells. Figure 3a shows that there 
is indeed a significant upregulation in M6PR surface expres-
sion on SKOV-3-luc cells following treatment with chemo-
therapy. However, mRNA levels (Fig. 3b) remain largely 
unchanged which suggests the potential shuttling of M6PR 
protein from the cytoplasm to the cell surface rather than de 
novo synthesis. This hypothesis was confirmed by immuno-
fluorescence; Fig. 3c shows upregulation of M6PR on the 
tumor cells’ surface following the addition of chemotherapy.
3-methyladenine (3-MA) is an autophagy inhibitor which 
blocks autophagosome formation through inhibition of type 
III PI3K [25, 26]; the process which leads to shuttling of 
M6PR to the cells’ surface [27]. As expected, the addition 
of 3-MA to chemotherapy resulted in a downregulation of 
tumor cell surface M6PR (Fig. 3a, c); mRNA levels did not 
change (Fig. 3b).
3-MA was further used in combination with chemother-
apy and T4 cells to assess the contribution of the shuttling 
of M6PR in the mechanisms of chemo-sensitization to T4 
immunotherapy (Fig. 3d, e). The addition of 3-MA to chem-
otherapy alone did not cause a change in SKOV-3-luc cell 
viability, as expected, when there were no T cells present. 
However, 3-MA caused a significant reversal in the reduc-
tion in tumor cell viability induced by combination treatment 
with chemotherapy and T4 cells, suggesting that exposure 
of M6PR to the tumor cell surface plays an essential role in 
synergistic killing.
Additionally, there was a significant increase in tumor 
intracellular Granzyme B expression as measured by flow 
cytometry following treatment with chemotherapy and T4 
cells (Fig. 3f). This was significantly reversed with 3-MA, 
further supporting the role of M6PR in facilitating cytotoxic 
killing by T cells.
Induction of G2/M arrest in ovarian cancer cell lines 
enhances sensitivity to T4 immunotherapy
Both paclitaxel and carboplatin are known to share a common 
mechanism that is the induction of G2/M arrest; which was 
observed in vitro in our ovarian cancer cells (Fig. 4a). Thi-
ostrepton is a cyclic peptide antibiotic which inhibits protein 
synthesis by blocking the binding of GTP to the 50S ribosomal 
subunit [28] and specifically targeting the G2/M regulatory 
transcription factor FOXM1 [29]. Treatment with Thiostrepton 
also induced a G2/M arrest in ovarian tumor cells (Fig. 4a). 
To assess the contribution of G2/M cell cycle on the synergy 
seen between chemotherapy and T4 immunotherapy, SKOV-
3-luc cells were treated with Thiostrepton for 48 h followed 
by T4 cells treatment. Figure 4b shows a significant reduction 
in tumor cell viability when cells were treated with Thiostrep-
ton and T4 cells, an effect which is similar to combination 
of carboplatin/paclitaxel and T4 immunotherapy. This result 
supports a role for G2/M arrest in enhancing ovarian cancer 
cells sensitivity to immunotherapy.
PD‑1 blockade augments chemo‑immunotherapy 
of ovarian cancer
Interestingly, 48 h treatment with either carboplatin or 
paclitaxel significantly increased cell surface expression 
of PD-L1 in SKOV-3 (Fig. 5a). Moreover, following the 
co-culture of SKOV-3-luc cells with T4 cells, there was a 
significant upregulation in the surface expression of PD-1 
on T4 cells at 24 and 48 h (Fig. 5b). This did not occur 
with either P4 cells (mock construct) or untransduced cells 
(activated T cells which have not been genetically modi-
fied). Considering the immunosuppressive nature of the 
PD-1 pathway in cancer, we investigated whether using a 
fully human monoclonal PD-1 blocking antibody would aid 
chemo-immunotherapy interactions in our system.
Treatment with anti-PD-1 in combination with chemo-
therapy and T4 immunotherapy resulted in a significant 
reduction in SKOV-3-luc (Fig. 5c, d) and OVCAR-4 cell 
viability (Fig. 5e, f) compared with chemotherapy alone, 
T4 alone, and importantly, combination chemotherapy-
T4 treatment. There was no change in cell viability when 
PD-1 blockade and chemotherapy were given with no T 
cells. Functionally, PD-1 blockade resulted in a significant 
increase in production of IFN-γ (Fig. 5g, h) and Granzyme 
B (Fig. 5i, j) by T4 cells, compared with T4 cells alone. 
In vivo, mice treated with paclitaxel, T4 cells and repeated 
doses of anti-PD-1 antibody had a significant reduction in 
Fig. 3  Role of tumor cell surface Mannose-6-Phosphate receptor 
(M6PR) in the synergy between chemotherapy and T4 cells. a Flow 
cytometry analysis of M6PR expression on SKOV-3-luc tumor cell 
surface following treatment with paclitaxel or carboplatin ± 3-Meth-
yladenine (3MA). b M6PR mRNA quantification from SKOV-3-luc 
cells treated with chemotherapy ± 3MA. c Immunofluorescence imag-
ing of SKOV-3-luc cells treated with chemotherapy ± 3MA showing 
cell surface M6PR, β actin cytoskeleton and nuclear staining (DAPI). 
d, e SKOV-3-luc cell viability following combination treatment 
of T4 and paclitaxel (d) or carboplatin (e) ± 3MA. f Flow cytomet-
ric analysis of intracellular expression of Granzyme B in SKOV-3-
luc following treatment with paclitaxel or carboplatin ± 3MA. Data 
show mean ± SEM (n = 3 for A-B, E-G, n = 1 for C-D); *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001, ns not significant
◂
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their tumor burden compared to mice receiving paclitaxel 
alone, anti-PD-1 antibody alone, or T4 cells alone (Fig. 6b, 
c). The tumor burden in the mice that received triple treat-
ment was lower at day 33 than in the mice that received 
paclitaxel and T4 cells. However, this difference was not 
significant.
Discussion
In this study, we have shown that combination treatment 
of ovarian cancer cells with paclitaxel or carboplatin and 
adoptive T cell therapy in the form of ErbB-targeted CAR 
T cells resulted in an enhanced anti-tumor effect; greater 
than when either therapy was used alone. Our previous 
work showed a clear synergy between platinum-based 
agents and T4 immunotherapy in vitro and in our in vivo 
mouse model of ovarian cancer. The current work carries 
this forward and shows that paclitaxel, another first-line 
agent that is commonly used in the management of ovar-
ian cancer, similarly synergizes with T4 immunotherapy. 
In this study, mice harboring intraperitoneal tumors were 
treated with a low dose of paclitaxel followed by adminis-
tration of T4 cells. This resulted in a substantial regression 
in the tumors.
Though it is tricky to translate the chemotherapy doses 
used on cell lines in this work to human-equivalent ones, 
based on where these doses lie in relation to the IC50, it 
would be reasonable to assume that they are ‘low’ doses.
It is worth noting that there was not much tumor regres-
sion following the administration of paclitaxel alone or T4 
cells as ‘low toxicity’ small dose and number were used, 
respectively, in view of a potential translation into the clinic.
PD-1 blockade further enhanced the anti-tumor activity 
achieved from combination treatment in vitro. The use of 
checkpoint inhibitors has thus far proven successful in many 
cancers and their use in ovarian cancer looks promising. 
The rationale behind using PD-1 blockade in this work was 
the finding that PD-1 was dramatically upregulated on the 
surface of T4 cells following co-culture with ovarian tumor 
cells. This finding was unique to T4 cells and not untrans-
duced cells or other CAR-engineered T cells (P4; target-
ing prostate specific membrane antigen). The interaction 
between the ErbB-rich tumor cells and T4 cells determined 
an increase in PD-1 on the surface of T cells. Additionally, 
treatment with chemotherapy alone determined an increased 
surface expression of PD-L1 on SKOV-3 tumor cells.
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Fig. 4  G2/M arrest enhances anti-tumor activity of T4 cells. a Flow 
cytometric cell cycle analysis of SKOV-3-luc treated with various 
doses of paclitaxel, carboplatin or Thiostrepton. b SKOV-3-luc cell 
viability following combination treatment of Thiostrepton ± T4. Data 
show mean ± SEM; ****p < 0.0001
Fig. 5  PD-1 blockade further enhances the synergy between chemo-
therapy and T4 cells. a Flow cytometric analysis of surface PD-L1 
expression on SKOV-3-luc after exposure to chemotherapy for 24 and 
48 h. b Flow cytometric analysis of surface PD-1 expression on T4 
cells alone or after co-culture with SKOV-3-luc cells for 24 and 48 h 
(P4 mock construct; UT untransduced T cells). c, d SKOV-3-luc cell 
viability following combination treatment of T4 and paclitaxel (c) 
or carboplatin (d) ± anti-PD-1 antibody. e, f OVCAR-4 cell viability 
following combination treatment of T4 and paclitaxel (e) or carbo-
platin (f) ± anti-PD-1 antibody. g, h IFN γ concentration in superna-
tants from SKOV-3-luc cells treated with paclitaxel (g) or carboplatin 
(h) ± T4 cells ± anti-PD-1 antibody. i, j Granzyme B concentration in 
supernatants from SKOV-3-luc cells treated with paclitaxel (i) or car-
boplatin (j) ± T4 cells ± anti-PD-1 antibody. Data show mean ± SEM 
using T cells from separate donors (n = 3); *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001
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PD-1 activation by PD-L1 is known to inhibit T cell 
proliferation and activity. Therefore, we hypothesized that 
blockade of PD-1 would enhance T cell function and activ-
ity in this system. Indeed, this was the case when an anti-
PD-1 antibody was used in combination with chemotherapy 
and T4 immunotherapy. Tumor cell viability in vitro was 
significantly reduced following PD-1 blockade in immortal-
ized cell lines treated with T4 alone and with both chemo-
therapy and T4 cells, the latter having a more significant 
effect. In vivo, similar findings were confirmed with PD-1 
blockade in combination with T4 cells and paclitaxel causing 
a significant regression in tumor burdens. Moreover, PD-1 
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Fig. 6  In vivo testing of using an anti-PD-1 antibody with T4 immu-
notherapy in mice-bearing SKOV-3-luc intraperitoneal tumor xeno-
grafts following treatment with paclitaxel. a Summary of the experi-
mental protocol. b Serial BLI of mice before and after treatment 
(black circle—paclitaxel, gray circle—T4 cells, black circle with gray 
dot—anti-PD-1 antibody). Data show mean ± SEM of 5 mice in each 
group, with background light emission detected from a tumor-free 
mouse; ****p < 0.0001 (day 35). c BLI images of all the mice before 
and after treatment, shown on the same scale
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blockade increased T4 activity as shown by the increase in 
IFNγ and Granzyme B levels in supernatants tested after 
treatment in vitro. IFNγ and Granzyme B levels were high 
when T4 cells were used and were significantly increased 
following PD-1 blockade. The levels appear to increase with 
increasing doses of paclitaxel or carboplatin, however, this 
dose-dependent trend was not significant.
As discussed above, combining traditional therapies with 
immunotherapies is becoming increasingly popular, espe-
cially due to some outstanding successes seen in combina-
torial approaches using checkpoint inhibitors. However, the 
mechanisms which govern synergistic interactions in com-
bination therapies are often unclear.
Both paclitaxel and carboplatin have been shown to 
induce apoptosis in tumor cells. In fact, DNA damage caused 
by chemotherapy leads to cleavage and activation of intracel-
lular caspases, initiating a proteolytic cascade and eventu-
ally cell death. Reversal of apoptosis can be achieved using 
the pan-caspase inhibitor Z-VAD, which binds to caspase 
proteases irreversibly, preventing the initiation of the pro-
teolytic cascade. Treating ovarian tumor cells with chemo-
therapy and Z-VAD resulted in a reversal of the anti-tumor 
activity observed following treatment with chemotherapy. 
When Z-VAD was used with chemotherapy and T4 cells, 
there was a partial, yet significant reversal in the reduction 
seen in tumor cell viability. The reversal was not complete, 
i.e., back to baseline, suggesting that caspase induction, or 
indeed apoptosis, was not the sole mechanism but was defi-
nitely contributing to the synergistic effect of our combina-
tion therapy.
Another potential mechanism we investigated was the 
role of autophagy and particularly M6PR, in our system. 
We showed that M6PR is upregulated on the tumor cell 
surface following chemotherapy treatment in vitro, both by 
flow cytometry and immunofluorescence. Functionally, co-
culturing T4 cells with tumor cells following chemotherapy 
resulted in an increase in intracellular tumor Granzyme B, 
possibly implicating M6PR as a ‘gateway’ for Granzyme B 
to enter the tumor.
It has been suggested that following chemotherapy M6PR 
is shuttled to the tumor cell surface rather than being syn-
thesized de novo [27]. To investigate if this was the case in 
our system, we looked at its mRNA and protein levels in 
SKOV-3-luc cells following chemotherapy treatment. Tumor 
mRNA levels of M6PR did not change which, together with 
our immunofluorescence and flow cytometry findings, 
contribute to the hypothesis of a chemotherapy-induced 
shuttling of M6PR rather than increased de novo synthe-
sis. To determine whether M6PR shuttling is involved in 
the synergistic interaction between chemotherapy and T4 
immunotherapy, we indirectly blocked its surface upregu-
lation using 3-MA—an autophagy inhibitor which blocks 
the formation of autophagosomes and subsequent release 
of M6PR to the tumor cell surface. Treating SKOV-3-luc 
cells with 3-MA resulted in a decrease in the surface M6PR 
expression, but not total levels. When used in combination 
with chemotherapy and T4 cells, 3-MA indeed resulted in a 
significant reversal in the anti-tumor effect seen with com-
bination therapy. Combination chemotherapy and 3-MA in 
the absence of T4 cells did not result in a change in tumor 
cell viability. Furthermore, intracellular Granzyme B lev-
els were significantly reduced in tumor cells treated with 
chemotherapy and 3-MA followed by T4 cells, suggesting 
that the “gateway” had been closed. These findings strongly 
implicate M6PR shuttling as another key process which sig-
nificantly contributes to the synergistic effect in our chemo-
immunotherapy approach.
Finally, it is known that paclitaxel exerts its anti-neoplas-
tic effect by disruption of the tumor cell cycle at the G2/M 
phase. Carboplatin, as well as causing DNA adducts and 
inter-and intra-strand links, also causes G2/M disruption. 
Therefore, we hypothesized that such cell cycle disruption 
at G2/M phase might be involved in sensitizing tumor cell 
to T4 immunotherapy.
To test this hypothesis, we induced G2/M arrest in tumor 
cells using Thiostrepton, and assessed if its combination 
with T4 immunotherapy had any enhanced anti-tumor effect. 
Thiostrepton is a cyclic peptide antibiotic which inhibits pro-
tein synthesis by blocking the binding of GTP to the 50S 
ribosomal subunit, and a specific inhibitor of the G2/M 
regulator FOXM1. Similar to chemotherapy, treatment with 
Thiostrepton resulted in a dose-dependent decrease in tumor 
cell viability. When combined with T4 cells, a significantly 
enhanced anti-tumor effect was observed. It is therefore 
likely that G2/M arrest contributes to sensitizing the tumor 
cells to immunotherapy. However, the reason as to why this 
may be happening remains unclear and requires further 
investigation.
In conclusion, our work demonstrates a therapeutic 
advantage to using combination chemotherapy and adoptive 
T cell therapy in the treatment of ovarian cancer. Addition-
ally, it provides a rationale for using checkpoint inhibitors, 
in particular PD-1 blockade which can further enhance the 
anti-tumor therapeutic effect of combination therapy. This 
most likely occurs by counteracting the increased upregu-
lation of PD-L1/PD-1 determined by chemotherapy and T 
cell–tumor contact, respectively, which we showed in our 
system. Moreover, we show how our three-agent approach, 
combining traditional chemotherapy, T4 immunotherapy and 
PD-1 blockade, is successful in vivo, in our ovarian cancer 
murine model.
It is evident that low-dose chemotherapy has a sensitizing 
effect on tumor cells, allowing better killing by cytotoxic 
lymphocytes. We have identified three mechanisms all of 
which significantly contribute to the synergistic interaction 
of chemo-immunotherapy against ovarian cancer cells. We 
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conclude that the mechanism of such synergy is multifaceted 
and is likely to involve other pathways which still remain to 
be investigated. Targeting these pathways may prove benefi-
cial to maximize the benefit from chemo-immunotherapy.
Though our findings are based on established ovar-
ian cancer cell lines used in in vitro and in vivo models, 
they give insights into the mechanisms of synergy between 
immunotherapy and chemotherapy; these would be expected 
to be similar in play in patients. Further studies in patients 
who may be on similar combination therapies are required 
and would add evidence to our findings.
Increasing our understanding of synergistic interactions 
is essential to better stratify patients and deliver appropriate 
combination treatments.
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